Planned
ADU-1805 - SRP-22C102
An Open-Label, Multicenter, Multi-Arm Phase 1 Study Evaluation the safety and Pharmacokinetics of ADU-1805 in Adults with Advanced Solid Tumors
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator :
C4971003
A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION
- Principal investigator : Dr. S. Woei-A-Jin
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT05626322
IMC-F106C-101
A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
- Principal investigator : Prof. Dr. O. Bechter
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT04262466
ONCOBAX®-AK EV.2101
A Phase 1/2 Study of Oncobax-AK Administered in Combintion with Immunotherapy to Patients with Advanced Solid Tumors
- Principal investigator : Prof. Dr. Benoit Beuselinck
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
TED16925 - SAR443216
A Phase 1/1b open-label, first-in-human, single agent, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR443216 in participants with relapsed/refactory HER2 expressing solid tumors
- Principal investigator : Prof. Dr. O. Bechter
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT05013554
Ongoing
BI 1403-0001
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Patients With Advanced or Metastatic Solid Tumors
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
- More information : NCT03449381
BI 1403-0002
A Phase Ia/Ib, Open Label, Dose-escalation Study of the Combination of BI 907828 With BI 754091 (Ezabenlimab) and BI 754111 and the Combination of BI 907828 With BI 754091(Ezabenlimab) Followed by Expansion Cohorts, in Patients With Advanced Solid Tumors
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
- More information : NCT03964233
BI 1403-0008 BRIGHTLINE-1
A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
- More information : NCT05218499
BP41628
An open label, multicenter, dose escalation and extension, phase Ia/Ib study to evaluate safety, pharmacokinetics, and therapeutic activity of RO7284755, a PD-1 targeted IL-2 variant (IL-2v) immunocytokine, alone or in combination with atezolizumab in participants with advanced and/or metastatic solid tumors
- Principal investigator : Prof. Dr. O. Bechter
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT04303858
GCT3009-01
Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts
- Principal investigator : Dr. S. Woei-A-Jin
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT04358458
IDRX-42-001
A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
- More information : NCT05489237
MBS8-101
A Phase I Multicentre, Open-label, Dose Escalation Study to Determine the Safety and Preliminary Efficacy of MBS8(1V270) Administered Intravenously to Cancer Patients With Advanced Solid Tumours
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
- More information : NCT04855435
TIG-006
A Multicenter, Open-Label, Phase I/II Study of EOS884448 (EOS-448) in Combination With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
- Principal investigator : Prof. Dr. O. Bechter
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information: NCT05060432
WP43295
A Phase IA/B, Open-Label, Multicenter Study Evaluating Safety, Pharmacokinetics, And Preliminary Clinical Activity Of Ro7276389 Alone And In Combination With Cobimetinib In Participants With Braf-V600 Mutation-Positive Advanced Solid Tumor And Participants With Braf-V600 Mutation-Positive Melanoma With Central Nervous System Metastases
- Principal investigator : Prof. Dr. O. Bechter
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
Closed
lNCB106385-102
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
CNIZ985B12101
A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL-15/sIL-15Rα)) in Combination With Spartalizumab in Patients With Check Point Inhibitor (CPI) Relapsed Advanced Solid Tumors and Lymphoma.
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
- More information : NCT04261439
BE43244
An Open-Label, Multicenter, Dose-Escalation, Phase I Study To Evaluate Safety, Pharmacokinetics, And Preliminary Anti-Tumor Activity Of RO7444973 In Participants With Advanced And/Or Metastatic Mage A4-Positive, Solid Tumors
- Principal investigator : Prof. Dr. O. Bechter
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT05129280
BP41054
An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant (Il-2v) Targeting Fibroblast Activation Protein-Α (Fap), In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreated Advanced And/Or Metastatic Melanoma
- Principal investigator : Prof. Dr. O. Bechter
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT03875079
BOEHRINGER INGELHEIM 1367.1
An open-label, phase Ia/Ib dose finding study with BI 894999 oral administered once a day in patients with advanced solid tumors, with repeated administration in patients with clinical benefit
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
- More information : NCT02516553
BOS172738-01
A Phase 1 Study of BOS172738 in Patients With Advanced Solid Tumors With RET Gene Alterations Including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
- More information : NCT03780517
BP42169
An open-label, multicenter, phase 1 study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7293583, a TYRP1-Targeting CD3 T-Cell Engager, in participants with metastatic melanoma
- Principal investigator : Prof. Dr. O. Bechter
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT04551352
COSMIC-021 XL184-021
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
- More information : NCT03170960
JAVELIN EMR 100070-001
A phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
- More information : NCT01772004
IDH305 CIDH305X210
A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
- More information : NCT02381886
IVIVC D0816C00024
A Phase 1, Randomised, Open-label, 4-Period Crossover Study to Develop an In Vitro-In Vivo Correlation for Olaparib Tablets in Subjects With Solid Tumor
- Principal investigator : Dr. K. Punie
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT03553108
LAG525 CLAG525X2101C
Open label multicenter phase I/II study of the safety and efficacy of LAG525 single-agent and in combination with PDR001 administered to patients with advanced malignancies
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
- More information : NCT02460224
NAPOLY CT-CL01
A phase I/II open-label, safety, pharmacokinetic and preliminary efficacy study of Cripec docetaxel in patients with solid tumors
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
- More information : NCT02442531
PD1-Fc-OX40L SL01-DEL-101
Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
- More information : NCT03894618
PIVOT-02 NKTR 16-214-02
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies
- Principal investigator : Prof. Dr. O. Bechter
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT02983045
ROLL-OVER CLAG CPDR001X2X01B
An Open-label, Multi-center Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
- More information : NCT04058756
SERVIER 001 CL1-81694-001
Phase I dose-escalation study of S81694 administered intravenously in adult patients with advanced/metastatic solid tumours
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
SERVIER 003 CL1-81694-003
Phase I/II Trial of S 81694 Administered Intravenously in Combination With Paclitaxel to Evaluate the Safety, Pharmacokinetic and Efficacy in Metastatic Breast Cancer
- Principal investigator : Prof. Dr. Hans Wildiers
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT03411161
SYNERGY IJB-SYNERGY-012017
A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- Principal investigator : Dr. K. Punie
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT03616886
TCD14678
A Phase 1/1b First-in-Human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With REGN2810 in Adult Patients With Advanced Solid Tumors
- Principal investigator : Prof. Dr. O. Bechter
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT03192345
TED15297
A Phase 1 First-in-Human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR441000 Administered Intratumorally as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
- Principal investigator : Prof. Dr. O. Bechter
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT03871348
THERADEX GCT1021-01
First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors
- Principal investigator : Prof. Dr. Patrick Schöffski
- Back-up principal investigator : Dr. K. Punie
- More information : NCT02988817